C5 and cardiomyopathy: This has ushered in a new treatment paradigm of TMA‐associated cardiomyopathy with C5 inhibitor eculizumab in addition to traditional use of anticoagulation, corticosteroids, plasma exchange, and IVIG [52, 53, 54].